.webp)
The global remote neurological monitoring market size was calculated at USD 2.45 billion in 2025 and is predicted to increase from USD 2.81 billion in 2026 to approximately USD 9.69 billion by 2035, expanding at a CAGR of 14.80% from 2026 to 2035. The market is driven by the rising integration of artificial intelligence (AI) and cloud analytics, which enable real-time predictive care and also early detection of neurodegenerative diseases outside traditional hospital settings.
The US active pharmaceutical ingredients market size accounted for USD 41.77 billion in 2025 and is predicted to increase from USD 44.46 billion in 2026 to approximately USD 79.80 billion by 2035, expanding at a CAGR of 6.69% from 2026 to 2035. The increasing demand for precision medicines, along with the technological advancements in the biopharma industry, has driven the market.
The US CAR T-cell therapy market size accounted for USD 2,299.97 million in 2025 and is predicted to increase from USD 2,684.84 million in 2026 to approximately USD 11,510.04 million by 2035, expanding at a CAGR of 17.47% from 2026 to 2035. The market is expanding rapidly due to increasing cancer incidence, growing adoption of personalized medicine, and continuous FDA approvals for new indications and products.
The US infant incubator market size accounted for USD 208.89 million in 2025 and is predicted to increase from USD 224.31 million in 2026 to approximately USD 442.25 million by 2035, expanding at a CAGR of 7.79% from 2026 to 2035. The market is driven by the rising prevalence of preterm births, increasing neonatal intensive care unit (NICU) admissions, advancements in neonatal care technologies, expanding healthcare infrastructure, and growing government investments in maternal and infant healthcare services.
The global CNS drug discovery market size was calculated at USD 9.80 billion in 2025 and is predicted to increase from USD 10.86 billion in 2026 to approximately USD 27.55 billion by 2035, expanding at a CAGR of 10.90% from 2026 to 2035. The rising prevalence of CNS disorders, the integration of AI and ML in drug discovery, and increased government support for clinical trials and funding are significant factors driving market growth.
The US pharmaceutical water market size accounted for USD 7.84 billion in 2025 and is predicted to increase from USD 8.66 billion in 2026 to approximately USD 17.97 billion by 2035, expanding at a CAGR of 8.65% from 2026 to 2035. The market is witnessing substantial growth due to the escalating burden of chronic diseases and the surging demand for high-quality biologics and sterile injectables. This expansion is supported by stringent FDA sterility standards and rapid advancements in water purification technologies, spurring massive investments in pharmaceutical manufacturing infrastructure.
The US biosensors market size accounted for USD 10.87 billion in 2025 and is predicted to increase from USD 11.69 billion in 2026 to approximately USD 20.42 billion by 2035, expanding at a CAGR of 6.51% from 2026 to 2035. The market is driven by the rising prevalence of chronic diseases, increasing demand for point-of-care testing, and advancements in wearable healthcare technologies.
The US bone grafts and substitutes market size accounted for USD 1.31 billion in 2025 and is predicted to increase from USD 01.38 billion in 2026 to approximately USD 2.25 billion by 2035, expanding at a CAGR of 5.56% from 2026 to 2035. Market growth is driven by the increasing prevalence of orthopedic disorders, rising sports injuries, a growing aging population, and expanding demand for minimally invasive surgical procedures.
The US cardiovascular drugs market size accounted for USD 28.42 billion in 2025 and is predicted to increase from USD 29.25 billion in 2026 to approximately USD 37.03 billion by 2035, expanding at a CAGR of 2.68% from 2026 to 2035. The market is witnessing substantial growth, mainly driven by the increasing prevalence of hypertension and heart failure, paired with a high demand for convenient oral medications and next-generation combination therapies that enhance patient compliance.
The US DNA synthesis market size was calculated at USD 1.90 billion in 2025 and is predicted to increase from USD 2.30 billion in 2026 to approximately USD 10.66 billion by 2035, expanding at a CAGR of 18.82% from 2026 to 2035. The growing investments in the biotechnology industry and technological advancements in the genetic engineering sector have accelerated the market expansion.
The US personalized medicine market size was calculated at USD 192.21 billion in 2025 and is predicted to increase from USD 207.15 billion in 2026 to approximately USD 427.17 billion by 2035, expanding at a CAGR of 8.31% from 2026 to 2035. The market is witnessing substantial growth due to the escalating burden of chronic diseases and the high demand for tailored treatments. This growth is supported by NGS and AI integration, spurring research and development in oncology and rare genetic disorders with precise, patient-specific therapies.
The US biotechnology market size accounted for USD 316.41 billion in 2025 and is predicted to increase from USD 361.07 billion in 2026 to approximately USD 1,142.07 billion by 2035, expanding at a CAGR of 13.70% from 2026 to 2035. The market is witnessing substantial growth due to an increasing prevalence of chronic and rare diseases, spurring high demand for precision biologics and gene therapies. Backed by significant research and development investments and FDA approvals, companies are prioritizing targeted platforms that provide highly effective, personalized patient care across critical therapeutic areas.
The US drug discovery market size accounted for USD 26.24 billion in 2025 and is predicted to increase from USD 28.66 billion in 2026 to approximately USD 63.02 billion by 2035, expanding at a CAGR of 9.16% from 2026 to 2035. The market is witnessing substantial growth due to escalating prevalence of chronic conditions, a surging demand for targeted precision therapies, and the integration of AI in preclinical research. This is further supported by significant private and federal research and development investments and robust clinical pipelines across major therapeutic areas.
The global dementia care market size accounted for USD 21.20 billion in 2025 and is predicted to increase from USD 22.97 billion in 2026 to approximately USD 46.97 billion by 2035, expanding at a CAGR of 8.40% from 2026 to 2035. The market is driven by the growing aging population. As life expectancy rises globally, the sheer volume of older adults, who are at the highest risk for neurodegenerative disorders, is leading to an unprecedented increase in dementia diagnoses.
The global stem cell therapy for neurological disorders market size accounted for USD 2.38 billion in 2025 and is predicted to increase from USD 2.81 billion in 2026 to approximately USD 12.67 billion by 2035, expanding at a CAGR of 17.90% from 2026 to 2035. The market is driven by technological advances in stem cell therapy manufacturing, a growing number of clinical trials, and the rising prevalence of neurological disorders.
The US diabetic foot ulcer treatment market size accounted for USD 3.66 billion in 2025 and is predicted to increase from USD 3.87 billion in 2026 to approximately USD 6.58 billion by 2035, expanding at a CAGR of 6.04% from 2026 to 2035. The market is witnessing substantial growth due to the growing diabetic population, along with an aging demographic. The market is further driven by advancements in advanced wound care and regenerative medicine, spurring clinical pipelines for targeted biologics and 3D-bioprinted tissues to improve limb preservation and quality of life.
The US healthcare cloud computing market size accounted for USD 23.58 billion in 2025 and is predicted to increase from USD 27.74 billion in 2026 to approximately USD 117.90 billion by 2035, expanding at a CAGR of 17.46% from 2026 to 2035. The market is witnessing substantial growth due to the rapid digital transformation in healthcare systems, increasing adoption of electronic health records (EHRs), rising demand for scalable data storage, and growing use of AI-enabled analytics to improve patient care, operational efficiency, and data security compliance.
The US biologics market size was calculated at USD 203.60 billion in 2025 and is predicted to increase from USD 223.60 billion in 2026 to approximately USD 525.67 billion by 2035, expanding at a CAGR of 9.95% from 2026 to 2035. The growing adoption of stem cell therapy for the treatment of cancers, along with technological advancements in genetic engineering, has boosted market growth.
The global duchenne muscular dystrophy therapeutics market size accounted for USD 6.80 billion in 2025 and is predicted to increase from USD 7.80 billion in 2026 to approximately USD 26.88 billion by 2035, expanding at a CAGR of 14.80% from 2026 to 2035. The market is driven by advances in genetic therapies and rising demand for rare disease treatments.
The global huntingtons disease market size was calculated at USD 1.42 billion in 2025 and is predicted to increase from USD 1.66 billion in 2026 to approximately USD 6.48 billion by 2035, expanding at a CAGR of 17.20% from 2026 to 2035. The increasing prevalence of Huntington’s disease, along with advances in clinical research and drug development, is a key driver of market growth.
The U.S. cell therapy manufacturing market size accounted for USD 1.71 billion in 2025 and is predicted to increase from USD 1.97 billion in 2026 to approximately USD 6.56 billion by 2035, expanding at a CAGR of 14.39% from 2026 to 2035. The market is driven by increasing clinical development and commercialization of cell-based therapies, rising investments in biopharmaceutical manufacturing infrastructure, and growing demand for scalable, automated production technologies.
The U.S. clinical trial supply and logistics market size accounted for USD 1.54 billion in 2025 and is predicted to increase from USD 1.66 billion in 2026 to approximately USD 3.13 billion by 2035, expanding at a CAGR of 7.35% from 2026 to 2035. The market is driven by the rising number of complex clinical trials, increasing demand for biologics and personalized medicine, and growing need for temperature-controlled and time-sensitive drug distribution across decentralized trial sites.
The global U.S. regenerative medicine market size was calculated at USD 19.77 billion in 2025 and is predicted to increase from USD 24.10 billion in 2026 to approximately USD 102.23 billion by 2035, expanding at a CAGR of 17.86% from 2026 to 2035. The market is driven by the increasing prevalence of chronic and degenerative diseases, rising investment in stem cell and gene therapy research, and growing adoption of advanced tissue engineering and personalized treatment approaches.
The global autoimmune neurological disorders market size accounted for USD 8.50 billion in 2025 and is predicted to increase from USD 9.17 billion in 2026 to approximately USD 17.79 billion by 2035, expanding at a CAGR of 7.90% from 2026 to 2035. This market is accelerating as advancements in targeted, patient-friendly biologics and novel delivery systems transform the long-term management of autoimmune neurological diseases.
The US central lab market size accounted for USD 2.37 billion in 2025 and is predicted to increase from USD 2.58 billion in 2026 to approximately USD 5.19 billion by 2035, expanding at a CAGR of 8.15% from 2026 to 2035. The market is experiencing strong growth driven by rising investments in biopharmaceutical R&D, increasingly complex clinical trial pipelines, and growing demand for standardized, high-quality biomarker testing. This expansion is further supported by the rapid adoption of advanced technologies such as artificial intelligence, laboratory automation, and decentralized clinical trial models, which are improving operational efficiency, data accuracy, and trial turnaround times.
The U.S. perfusion system market size accounted for USD 6,78,407.71 thousand in 2025 and is predicted to increase from USD 7,35,773.48 thousand in 2026 to approximately USD 16,24,531.09 thousand by 2035, expanding at a CAGR of 9.20% from 2026 to 2035. The market is witnessing substantial growth due to the increasing prevalence of cardiovascular diseases, an aging population, and a surge in complex cardiothoracic and organ transplant surgeries.
The global neuroimmunology market size accounted for USD 37.80 billion in 2025 and is predicted to increase from USD 41.15 billion in 2026 to approximately USD 91.88 billion by 2035, expanding at a CAGR of 8.90% from 2026 to 2035. The market is driven by the surging global incidence of neurological and autoimmune disorders, such as multiple sclerosis, Alzheimer's, and Parkinson's, combined with breakthroughs in targeted drug discovery and advanced diagnostic imaging.
The global aquafeed and aquaculture additive market size accounted for USD 78.40 billion in 2025 and is predicted to increase from USD 83.73 billion in 2026 to approximately USD 150.17 billion by 2035, expanding at a CAGR of 6.80% from 2026 to 2035. The market growth is attributed to increasing global seafood consumption, expanding commercial aquaculture production, and rising adoption of functional and sustainable feed technologies.
The U.S. systemic inflammatory response syndrome treatment market size was calculated at USD 4.88 billion in 2025 and is predicted to increase from USD 5.28 billion in 2026 to approximately USD 8.83 billion by 2035, expanding at a CAGR of 6.11% from 2026 to 2035. The market is driven by rising SIRS cases, improved diagnostic technologies, and stronger critical care protocols.
The U.S. insulin pump market size was calculated at USD 2.29 billion in 2025 and is predicted to increase from USD 2.48 billion in 2026 to approximately USD 5.13 billion by 2035, expanding at a CAGR of 8.40% from 2026 to 2035. The market is driven by the integration of artificial intelligence in hybrid closed-loop systems and the growing burden of diabetes.
The U.S. viral vectors and plasmid DNA manufacturing market size accounted for USD 2.84 billion in 2025 and is predicted to increase from USD 3.30 billion in 2026 to approximately USD 11.69 billion by 2035, expanding at a CAGR of 15.20% from 2026 to 2035. The market growth is attributed to increasing gene therapy commercialization, expanding clinical trial activity, and rising investments in advanced biomanufacturing infrastructure.
The global materials for bone implants market size accounted for USD 5.80 billion in 2025 and is predicted to increase from USD 6.24 billion in 2026 to approximately USD 11.96 billion by 2035, expanding at a CAGR of 7.50% from 2026 to 2035. The market is driven by the increasing cases of bone injury and dental problems and advancements in material modification.
The global neuroinflammation market size accounted for USD 8.60 billion in 2025 and is predicted to increase from USD 9.53 billion in 2026 to approximately USD 23.81 billion by 2035, expanding at a CAGR of 10.90% from 2026 to 2035. The increasing geriatric population with neurodegenerative disorders and the rising number of clinical trials around the globe are key drivers of the growth of the market.
The global precision neurology market size was calculated at USD 18.40 billion in 2025 and is predicted to increase from USD 21.07 billion in 2026 to approximately USD 70.63 billion by 2035, expanding at a CAGR of 14.60% from 2026 to 2035. The increasing prevalence of neurological disorders and advances in precision healthcare research are key drivers of market growth.
The global multiple sclerosis diagnostics market size accounted for USD 5.70 billion in 2025 and is predicted to increase from USD 6.20 billion in 2026 to approximately USD 12.88 billion by 2035, expanding at a CAGR of 8.80% from 2026 to 2035. The market is driven by technological advancements in neuroimaging, specifically the use of high-resolution, 3T magnetic resonance imaging (MRI) scanners.
The global multiple sclerosis therapeutics market size accounted for USD 34.80 billion in 2025 and is predicted to increase from USD 37.16 billion in 2026 to approximately USD 66.80 billion by 2035, expanding at a CAGR of 6.90% from 2026 to 2035. The market is driven by rising multiple sclerosis cases, increasing adoption of biologic therapies, and advancements in disease-modifying treatments.
The global CNS biomarkers market size accounted for USD 7.80 billion in 2025 and is predicted to increase from USD 8.81 billion in 2026 to approximately USD 26.13 billion by 2035, expanding at a CAGR of 12.90% from 2026 to 2035. The market is driven by the increasing use of CNS biomarkers, the growing need for understanding various neurological disorders, and rapid advancements in biomarker technologies.
The global amyloid beta therapeutics market size is predicted to increase from USD 6.12 billion in 2026 to approximately USD 26.50 billion by 2035, expanding at a CAGR of 17.80% from 2026 to 2035. The market is driven by rising Alzheimer’s cases and demand for safer targeted therapies.
The global alzheimers disease diagnostics market size accounted for USD 9.40 billion in 2025 and is predicted to increase from USD 10.42 billion in 2026 to approximately USD 26.21 billion by 2035, expanding at a CAGR of 10.80% from 2026 to 2035. The market is driven by the growing demand for early Alzheimer’s detection and minimally invasive, biomarker-based diagnostics.
The global parkinsons disease biomarkers market size accounted for USD 1.35 billion in 2025 and is predicted to increase from USD 1.54 billion in 2026 to approximately USD 4.88 billion by 2035, expanding at a CAGR of 13.80% from 2026 to 2035. The market is driven by the rising demand for early diagnosis and disease-modifying therapies.
The global tau protein targeting therapeutics market size was calculated at USD 1,100.00 million in 2025 and is predicted to increase from USD 1,314.50 million in 2026 to approximately USD 6,534.16 million by 2035, expanding at a CAGR of 19.50% from 2026 to 2035. The rising prevalence of neurodegenerative disorders, along with increased research activities and government healthcare initiatives, is a key driver of market growth.
The global hematopoietic stem cell transplantation market size accounted for USD 11.80 billion in 2025 and is predicted to increase from USD 12.69 billion in 2026 to approximately USD 24.32 billion by 2035, expanding at a CAGR of 7.50% from 2026 to 2035. The rising incidence of blood cancers and advancements in stem cell transplant technologies drive the market.
The global hemophilia market size was estimated at USD 12.50 billion in 2025 and is predicted to increase from USD 13.31billion in 2026 to approximately USD 23.46 billion by 2035, expanding at a CAGR of 6.50% from 2026 to 2035. The market is driven by rising diagnosis rates and advanced prophylactic therapies.
The global non-hodgkin's lymphoma market size was estimated at USD 14.10 billion in 2025 and is predicted to increase from USD 15.00 billion in 2026 to approximately USD 26.22 billion by 2035, expanding at a CAGR of 6.40% from 2026 to 2035. The market is driven by growing prevalence and demand for targeted, convenient treatments, driving significant research and development into novel CAR-T and antibody therapies to improve survival rates and patient convenience.
The global additive manufacturing for medical devices market size accounted for USD 4.60 billion in 2025 and is predicted to increase from USD 5.42 billion in 2026 to approximately USD 23.87 billion by 2035, expanding at a CAGR of 17.90% from 2026 to 2035. The additive manufacturing for medical devices market is driven by demand for patient-specific implants and rapid advancements in biocompatible 3D printing technologies.
The global immunochemistry instruments and reagents market size accounted for USD 26.20 billion in 2025 and is predicted to increase from USD 28.14 billion in 2026 to approximately USD 53.50 billion by 2035, expanding at a CAGR of 7.40% from 2026 to 2035. The immunochemistry instruments & reagents market is driven by growing demand for accurate and rapid diagnostic testing.
The global hospital acquired infection control market size accounted for USD 22.30 billion in 2025 and is predicted to increase from USD 23.79 billion in 2026 to approximately USD 42.65 billion by 2035, expanding at a CAGR of 6.70% from 2026 to 2035. The market is driven by rising incidences of hospital-acquired infections and demand for advanced infection prevention solutions.
The global breast lesion localization methods market size accounted for USD 720.00 million in 2025 and is predicted to increase from USD 770.00 million in 2026 to approximately USD 1,480.00 million by 2035, expanding at a CAGR of 7.47% from 2026 to 2035. The breast lesion localization methods market is driven by rising cases of breast cancer and demand for minimally invasive diagnostics.
The global injectable peptides drugs market size accounted for USD 48.60 billion in 2025 and is predicted to increase from USD 53.07 billion in 2026 to approximately USD 117.18 billion by 2035, expanding at a CAGR of 9.20% from 2026 to 2035. The injectable peptides drug market is driven by the rising prevalence of chronic diseases and the demand for targeted therapies.
The global in vivo CAR-T therapy market size accounted for USD 650.00 million in 2025 and is predicted to increase from USD 861.25 million in 2026 to approximately USD 10,841.07 million by 2035, expanding at a CAGR of 32.50% from 2026 to 2035. The market growth is driven by the rising prevalence of cancer, ongoing advancements in healthcare, and the increasing number of clinical trials focused on in vivo CAR-T therapy.